Sanara MedTech Inc. (NASDAQ:SMTI) Receives Consensus Recommendation of "Reduce" from Analysts

Key Points

• Analysts have a consensus “Reduce” rating on Sanara MedTech, with one sell rating and four hold ratings among five analysts. The average 12-month price target is $35.00, below the stock’s reported opening price of $34.09.
• Recent research actions were largely cautious: HC Wainwright and Lake Street Capital downgraded the shares to neutral or hold, while Weiss Ratings maintained a sell rating.
• SMTI has gained significantly from its 12-month low of $16.05 and trades near its $35.95 high, but the company reports a negative price-to-earnings ratio and institutional investors own only 8.10% of outstanding shares.

Shares of Sanara MedTech Inc. (NASDAQ:SMTI - Get Free Report) have received an average recommendation of "Reduce" from the five analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $35.00.

Several equities research analysts recently issued reports on SMTI shares. HC Wainwright lowered shares of Sanara MedTech from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $36.00 to $35.00 in a research note on Thursday, July 30th. Wall Street Zen downgraded shares of Sanara MedTech from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 1st. Weiss Ratings restated a "sell (e+)" rating on shares of Sanara MedTech in a report on Friday, July 17th. Lake Street Capital downgraded Sanara MedTech from a "buy" rating to a "hold" rating and set a $35.00 price target for the company. in a research note on Thursday, July 30th. Finally, Zacks Research raised Sanara MedTech from a "strong sell" rating to a "hold" rating in a research note on Wednesday, June 10th.

Hedge Funds Weigh In On Sanara MedTech

Institutional investors have recently made changes to their positions in the business. Rhumbline Advisers raised its stake in Sanara MedTech by 14.9% during the 1st quarter. Rhumbline Advisers now owns 3,714 shares of the company's stock valued at $115,000 after purchasing an additional 483 shares during the last quarter. Geode Capital Management LLC grew its position in Sanara MedTech by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 79,049 shares of the company's stock worth $1,846,000 after purchasing an additional 546 shares during the last quarter. State Street Corp increased its holdings in shares of Sanara MedTech by 1.1% during the 4th quarter. State Street Corp now owns 62,289 shares of the company's stock worth $1,454,000 after purchasing an additional 690 shares during the period. Bank of America Corp DE increased its holdings in shares of Sanara MedTech by 44.1% during the 3rd quarter. Bank of America Corp DE now owns 3,181 shares of the company's stock worth $101,000 after purchasing an additional 973 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in shares of Sanara MedTech by 351.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company's stock worth $48,000 after purchasing an additional 1,171 shares during the period. 8.10% of the stock is currently owned by institutional investors.

Sanara MedTech Stock Performance

SMTI stock opened at $34.09 on Friday. The company has a quick ratio of 2.05, a current ratio of 2.28 and a debt-to-equity ratio of 6.59. The company has a market capitalization of $312.26 million, a price-to-earnings ratio of -9.04 and a beta of 1.13. Sanara MedTech has a 12 month low of $16.05 and a 12 month high of $35.95. The firm has a 50 day moving average of $24.92 and a two-hundred day moving average of $21.64.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company's core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source